Developing a new method for producing ultra-pure mRNA for therapies
Official title: Rapid and Ultra-Pure mRNA Production with Next-Generation RNA Polymerases
Funded at Cisterna Biologics, INC. · NIH-11184941 · Data updated 2026-11-12
This study is working on a new way to make super clean mRNA, which could lead to better and safer treatments for conditions like cancer and enzyme deficiencies, helping patients get the most out of their therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cisterna Biologics, INC. NIH-funded |
| Lab location | 1 site (Oceanside, United States) |
| Project start | June 5, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $350,000 |
| NIH project number | 1R41GM159477-01 |
| Project ID | NIH-11184941 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would include patients requiring mRNA-based therapies, particularly those with cancer or genetic disorders needing enzyme replacement.
✕Less likely to help
Patients who are not candidates for mRNA therapies or those with conditions that do not require such treatments may not benefit from this research.
What this research studies
This research focuses on creating a novel process for producing ultra-pure mRNA, which is crucial for effective treatments such as cancer immunotherapy and enzyme replacement therapies. The approach involves using cold-adapted RNA polymerases that work efficiently at low temperatures, minimizing harmful byproducts that can cause adverse immune reactions. By employing a proprietary purification technology, the goal is to eliminate contaminants entirely, enhancing the safety and efficacy of mRNA therapeutics. Patients may benefit from improved treatment options that require high-dosage and frequent administration.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective mRNA-based therapies for various conditions, including cancer.
How similar studies have gone: Other research has shown promise in improving mRNA production and purification methods, indicating potential for success with this novel approach.
Where this research is happening
-
Cisterna Biologics, INC.
Oceanside, United States Active
Researchers
- Principal investigator: Bhaskaran, Hari — Cisterna Biologics, INC.
- Study coordinator: Bhaskaran, Hari
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.